Company Name, Ticker, Competitors, else..

Acrivon Therapeutics Inc (NASDAQ: ACRV)

Sector • Healthcare Industry • Major Pharmaceutical Preparations

Industry • Major Pharmaceutical Preparations

Sector • Healthcare

Acrivon Therapeutics Inc 's

Name: Acrivon Therapeutics Inc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

ACRV Sales vs. its Competitors Q2 2026

Comparing the current results to its competitors, Acrivon Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 7.37 %, recorded in the same quarter.

• List of ACRV Competitors

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

Acrivon Therapeutics Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 424.07 %

<< ACRV Stock Performance Comparisons

<< See the full list of ACRV competitors

*Market share is calculated based on total revenue.

News about Acrivon Therapeutics Inc Contracts

Acrivon Therapeutics' ACR-368 Shows Promising Results in Ovarian and Endometrial Cancers

April 24, 2024
Acrivon Therapeutics, a leading pharmaceutical company, presented initial positive clinical data for their investigational drug ACR-368 and highlighted progress in their pipeline program at a recent Corporate RandD event. The data showcased the efficacy of ACR-368 in treating ovarian and endometrial cancers, as well as the validation of their AP3 patient selection platform and the accelerated timeline for ACR-2316, a potentially groundbreaking inhibitor. This article aims to delve into the details of these findings and their significance for patients with gynecological cancers.ACR-368 Demonstrates High Overall Response Rate:The Phase 2b clinical data presented by Acrivon Therapeutics revealed a 50% confirmed...

ACRV's Stock Performance relative to its Competitors

Publicly Traded Peers of Acrivon Therapeutics Inc

Zymeworks Inc
Share Performance

+6.12%

30 Days

Zymeworks Inc

Profile

Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.

More about Zymeworks Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 2,019.360 mill.	$ 37.127 mill.	$ -149.992 mill.

Ocean Biomedical Inc
Share Performance

+700.00%

This Quarter

Ocean Biomedical Inc

Profile

Ocean Biomedical develops biopharmaceutical products licensed from research institutions.

More about Ocean Biomedical Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 0.073 mill.	$ - mill.	$ -28.983 mill.

Nextcure Inc
Share Performance

+8.65%

One Year

Nextcure Inc

Profile

NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.

More about Nextcure Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 32.018 mill.	$ - mill.	$ -42.748 mill.

Nuvalent Inc
Share Performance

+0.46%

30 Days

Nuvalent Inc

Profile

Nuvalent Inc's business model entails developing innovative pharmaceutical solutions utilizing its proprietary technology and expertise.

More about Nuvalent Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 9,751.979 mill.	$ - mill.	$ -450.074 mill.

Nuvation Bio Inc
Share Performance

-11.85%

30 Days

Nuvation Bio Inc

Profile

Nuvation Bio Inc's business model is centered around the development of novel therapies for the treatment of cancer and other diseases.

More about Nuvation Bio Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 2,139.704 mill.	$ 169.551 mill.	$ -149.827 mill.

47 more competitors available

Sources: Acrivon Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Thursday, September 17, 2026 9:30 AM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Acrivon Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.